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376 ABSTRACT 
77
78 Topic: A comparison between ranibizumab and bevacizumab of the incidence of systemic 
79 serious adverse events (SAEs) among patients with neovascular age-related macular 
80 degeneration (nAMD) who participated in a large-scale randomized trial.  Use of individual 
81 patient data, rather than aggregate data, allowed adjustment for strong predictors of SAEs.
82 Clinical relevance:  Relative safety of ranibizumab and bevacizumab is important in choosing 
83 an anti-VEGF drug for the hundreds of thousands of patients with nAMD treated each year 
84 worldwide.
85 Methods:  Results of a Cochrane aggregate meta-analysis of the relative efficacy and safety of 
86 bevacizumab and ranibizumab that used searches of bibliographic databases and clinical trial 
87 registries as of March 14, 2014 and hand searching were reviewed to identify 6 large-scale, 
88 multicenter clinical trials.  Individual patient data on SAEs, assigned drug and dosing regimen, 
89 and baseline prognostic factors were requested from the leaders of the 6 trials.  A two-stage 
90 approach was used to estimate relative risks and 95% confidence intervals (CIs) from Cox 
91 proportional hazards models adjusting for baseline prognostic factors.  The primary outcome 
92 measure was development of ≥1 SAE; secondary outcome measures were death, 
93 arteriothrombotic events, events associated with systemic anti-VEGF therapy, and events not 
94 associated with systemic anti-VEGF therapy.
95 Results:  Individual patient data were received from 5 trials to provide information on 3052 
96 patients.  There were no large imbalances between drug groups on baseline factors.  The 
97 adjusted relative risk (95% CI) for bevacizumab relative to ranibizumab was 1.06 [(0.84, 1.35); 
98 p=0.61] for ≥1 SAEs.  For secondary outcomes, adjusted relative risks were 0.99 [(0.69, 1.43); 
99 p=0.97] for death, 0.89 [(0.62, 1.28); p=0.53] for arteriothrombotic events, 1.10 [(0.81, 1.50); 
100 p=0.54] for events related to anti-VEGF treatment, and 1.11 [(0.87, 1.40); p=0.40] for events not 
101 related to anti-VEGF treatment.
4102 Conclusion: Our findings support the absence of large differences in risk of systemic serious 
103 adverse events between these two anti-VEGF drugs; i.e., relative risks of ≥1.5 are unlikely.  
104 Because additional head-to-head trials are unlikely, any further investigation of differential risk 
105 between anti-VEGF agents will only be achieved though post-marketing surveillance or through 
106 the interrogation of healthcare databases.
107
5108 The management and prognosis of patients with neovascular age-related macular 
109 degeneration (AMD) changed dramatically in 2005 with the release of results from Phase III 
110 clinical trials of intravitreally administered ranibizumab (Lucentis; Genentech, Inc., South San 
111 Francisco, CA), an inhibitor of all active forms of vascular endothelial growth factor (VEGF).1,2  
112 On average, eyes treated with ranibizumab gained visual acuity while untreated eyes or eyes 
113 treated with photodynamic laser therapy lost substantial visual acuity. While waiting for approval 
114 from regulatory agencies in the United States and Europe, ophthalmologists began using 
115 intravitreal bevacizumab off label to treat neovascular AMD because it was structurally similar to 
116 ranibizumab (Avastin; Genentech, Inc., South San Francisco, CA), available for use because it 
117 had been approved for treatment of cancer, and was inexpensive. Short-term outcomes related 
118 to vision and retinal morphology after treatment with bevacizumab appeared similar to those of 
119 ranibizumab, leading to rapid adoption of bevacizumab as first-line therapy. The fact that after 
120 ranibizumab was approved by the Food and Drug Administration, ranibizumab was sold for 
121 approximately $2000 per dose in the United States compared to $50 for bevacizumab, amplified 
122 the need for comparison of longer term efficacy and safety between the two drugs.3
123 Planning for large-scale, multicenter clinical trials of the two drugs was initiated in 6 
124 different countries.  These multicenter clinical trials were: the Comparison of Age-related 
125 Macular Degeneration Treatments Trials (CATT) in the United States,  the Alternative 
126 Treatments to Inhibit VEGF in Age-related Choroidal Neovascularization (IVAN) in the United 
127 Kingdom, the Groupe d’Etude Français Avastin versus Lucentis dans la DMLA néovasculaire 
128 (GEFAL) in France, the Multicenter Anti-VEGF Trial in Austria (MANTA),  Lucentis Compared to 
129 Avastin Study (LUCAS) in Norway, and Bevacizumab and Ranibizumab in Age-related Macular 
130 Degeneration (BRAMD) in the Netherlands.4-12  In 2011, CATT was the first of the trials to 
131 provide 1-year results.4  The mean change in visual acuity under treatment with bevacizumab 
132 was non-inferior to the mean change in visual acuity under treatment with ranibizumab. The 
133 results on efficacy from the other multicenter clinical trials have been consistent with no 
6134 difference or only a small difference in change in visual acuity between drugs after the initiation 
135 of treatment; a recent meta-analysis yielded a mean difference (95% confidence interval [CI]) of 
136 -0.5 letters (-1.6 to +0.6), with a negative difference indicating less improvement in eyes treated 
137 with bevacizumab.13
138 However, the results from one of the clinical trials raised concerns on the safety of 
139 bevacizumab relative to ranibizumab.  In CATT, the proportion of patients with 1 or more 
140 systemic serious adverse events (SAEs) at 1 year was higher with bevacizumab than 
141 ranibizumab (24.1% vs. 19.0%; adjusted relative risk, 1.29; 95% CI [1.01, 1.66]) and the 
142 elevated risk persisted at 2 years (39.9% vs. 31.7%; adjusted relative risk, 1.30; 95% CI [1.07, 
143 1.57]; P=0.009).4,5  Rates of death and arteriothrombotic events were similar for the two drugs.  
144 As the results from other clinical trials became available, several groups of investigators 
145 performed meta-analyses of overall SAEs and specific adverse events based on the aggregate 
146 data.13-19   The most comprehensive analysis of SAEs was a Cochrane review led by Moja 
147 consisting of 3665 patients with 3356 from the 6 multicenter clinical trials noted above and 309 
148 patients from 3 smaller-scale studies.15  The combined risk ratio for 1 or more systemic adverse 
149 events was 1.08, 95% CI (0.90, 1.31). Similar to the researchers conducting previous meta-
150 analyses, Moja et al concluded that there was no strong evidence of a difference in risk but that 
151 the data available was not sufficient to rule out clinically important differential risks, particularly 
152 for specific adverse events.
153 The purpose of the present investigation was to use individual patient data, rather than 
154 aggregate data, from the large-scale multicenter clinical trials evaluating bevacizumab and 
155 ranibizumab for treatment of neovascular age-related macular degeneration to estimate the 
156 relative risk of serious systemic adverse events and selected specific SAEs adjusted for 
157 prognostic baseline variables.  Although randomization is expected to provide treatment groups 
158 that are balanced on predisposing conditions, small imbalances on strong prognostic factors 
159 such as age, smoking, hypertension, and use of anti-coagulant medications can artificially 
7160 inflate or deflate the difference in risk between the two drugs. Accounting for covariates also 
161 may increase the precision of the estimates of the relative risk.
162 METHODS 
163 Clinical Trials Included 
164 Investigators for a recent Cochrane aggregate meta-analysis of the relative efficacy and 
165 safety of intravitreal bevacizumab and ranibizumab searched electronic bibliographic databases 
166 and clinical trial registries as of March 14, 2014 and used hand searching to identify 5249 
167 records that might address the topic.13  Nine trials were identified by the Cochrane investigators. 
168 We targeted for this review the six multicenter, randomized clinical trials that compared 
169 bevacizumab to ranibizumab, reported counts for patients with 1 or more SAEs, had at least 1 
170 patient reported to have an SAE, and had results published or presented at a national meeting 
171 by December 2015.  Eligibility criteria for all the trials specified enrollment of eyes with active 
172 neovascularization.
173 Specification of Outcomes and Effect Measures
174 The primary outcome for the review was the percentage of patients experiencing 1 or 
175 more SAEs as defined by the Food and Drug Administration of the United States and the 
176 European Medicines Agency.20,21  This definition includes all deaths, life-threatening events, 
177 hospitalizations, events resulting in persistent or significant disability, important medical events, 
178 and congenital anomalies.  Secondary outcomes were the specific SAEs of death, 
179 arteriothrombotic events as defined by the Antiplatelet Trialists’ Collaboration (APTC), events 
180 previously associated with systemic anti-VEGF treatment (arteriothrombotic events [including 
181 but not limited to myocardial, cerebellar, and cerebral ischemia and infarction, coronary artery 
182 occlusion, transient ischemic attack, cerebrovascular accidents, and embolism], systemic 
183 hemorrhage [including duodenal, gastric, gastrointestinal, rectal, respiratory tract, urogenital, 
184 cerebral, intracranial hemorrhage and hematoma], cardiac failure [including congestive heart 
185 failure], venous thrombotic events [including pulmonary embolism, deep vein thrombosis, and 
8186 thrombosis], hypertension [including hypertensive heart disease and accelerated hypertension], 
187 vascular death), and events not previously associated with systemic anti-VEGF treatment.22-24  
188 Because of an imbalance reported from CATT, gastrointestinal hemorrhages were also 
189 summarized.  The difference in risk was summarized by the relative risk (hazard ratio) and the 
190 associated 95% confidence interval.
191 Data Collection and Statistical Analysis 
192 The Coordinating Center for CATT managed the data and performed the statistical 
193 analyses for the review.  The lead author or primary contact person as listed in a registry of 
194 clinical trials was invited to provide individual patient data.  Data were to be provided in two 
195 electronic data files containing only de-identified data.  The first file contained age at enrollment, 
196 gender, drug (bevacizumab or ranibizumab), dosing regimen (pro re nata, monthly, or treat-and-
197 extend), study eye (right or left), smoking status at baseline (current, past, or never), diabetes at 
198 baseline (yes or no), use of medications for hypertension at baseline (yes or no), treatment of 
199 the fellow eye with anti-VEGF drugs during the study period (drug and duration of use), use of 
200 aspirin at baseline (yes or no), use of an anti-coagulant at baseline (yes or no), and number of 
201 days between enrollment and the last date of data collection for SAEs.  The individual patient 
202 characteristics at baseline were chosen because they are known to be strong prognostic factors 
203 for one or more of the outcomes of interest.  The second file contained one record for each SAE 
204 and included the number of days between study enrollment and the SAE, the Medical Dictionary 
205 for Regulatory Activities (MedDRA) code number, and MedDRA preferred term for the SAE.  
206 The period of observation was 2 years after study entry for CATT and IVAN and 1 year for the 
207 other 4 studies.
208 A two-stage approach was used for each meta-analysis.25,26  In the first stage, a Cox 
209 proportional hazards model of the outcome of interest was used for each individual clinical trial 
210 to provide a relative risk adjusted for baseline prognostic factors and to provide the associated 
211 95% confidence interval for the risk of using bevacizumab compared to using ranibizumab.  
9212 Only the first observation of the outcome of interest was included in the analysis. The Cox 
213 models included dosing regimen (for CATT and IVAN only because these trials include both 
214 monthly and as-needed regimens), age, gender, smoking status, diabetes status, use of 
215 medications for or a diagnosis of hypertension, use of aspirin, and use of anti-coagulants when 
216 data for these variables were available. For the second stage, OpenMeta[Analyst] statistical 
217 software for meta-analyses was used to produce a weighted average of the trial specific relative 
218 risk from the first stage (http://www.cebm.brown.edu/open_meta/ accessed 10/20/2015). 
219 Random effects models using maximum likelihood estimation were chosen to reflect both the 
220 within-study variability (95% CIs estimated in stage 1) and the between-study variability (the 
221 difference between the point estimates from stage 1 and the pooled estimate).27  Heterogeneity 
222 among trial results was evaluated with the I2 statistic.  For purposes of comparison, an 
223 unadjusted meta-analysis was performed with OpenMeta[Analyst] using aggregate data as for 
224 stage 2 of the adjusted meta-analysis. Individual patient data were not provided from MANTA.9  
225 As a secondary analysis, the unadjusted risk estimates for 1 or more SAEs and for death from 
226 based on the publication of 1-year MANTA results were used for the second stage of the 
227 adjusted meta-analysis.  Because the conversion from the published data to the other outcomes 
228 of interest could not be made without more details on type of the SAEs, no secondary analyses 
229 were performed for the other outcomes of interest.
230 The data files from the 5 clinical trial groups providing individual patient data were checked 
231 for completeness of the data requested and for consistency with published aggregate results.  
232 Data files for CATT, IVAN, GEFAL, and LUCAS, matched the published aggregate findings for 
233 the safety analysis with respect to number of patients and number of patients with 1 or more 
234 systemic SAE in each treatment group.  Serious ocular adverse events were not counted as 
235 systemic adverse events for this analysis.11 There was 1 less patient assigned to bevacizumab 
236 in the data files from BRAMD than reported in published results.12  Nine patients in LUCAS, who 
237 had no serious adverse events, were excluded from the efficacy analysis in LUCAS because of 
10
238 serious non-compliance with the treatment protocol and were excluded from the adjusted 
239 analysis in this report. When data on use of medications for hypertension were not available, 
240 data on a diagnosis of hypertension were used instead.
241
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242 RESULTS
243 The baseline data available from each clinical trial are summarized in Table 1.  Among the 
244 five clinical trials providing individual patient data, age, gender, diabetes status, and 
245 hypertension status (as defined in the parent trial) were available in all trials.  There were only 
246 small imbalances between the bevacizumab and ranibizumab groups on the baseline 
247 characteristics.
248 There were 403 (26.6%) patients among 1513 treated with bevacizumab and 366 (23.8%) 
249 among 1539 treated with ranibizumab who had 1 or more systemic SAE.  The numbers of 
250 patients in each treatment group in each study are provided in Table 2.  Adjusted meta-analysis 
251 results are shown in Figure 1 and compared to the unadjusted results in Table 3.   The pooled 
252 adjusted relative risk for bevacizumab compared to ranibizumab was 1.06, 95% CI (0.84, 1.35).  
253 The adjusted relative risk differs little from the unadjusted relative risk of 1.08.  When the 
254 aggregate data from MANTA was included in the adjusted analysis, the relative risk was 1.09, 
255 95% CI (0.89,1.35).  The adjusted relative risk for death was 0.99, 95% CI (0.69, 1.43) (Figure 2 
256 available at http://www.aaojournal.org). When the aggregate data from MANTA was included in 
257 the adjusted analysis, the relative risk was 1.01, 95% CI (0.71,1.45). Estimated risk for APTC 
258 arteriothrombotic events was lower for bevacizumab (0.89) but with the 95% confidence interval 
259 spanning (0.62, 1.28) (Figure 3 available at http://www.aaojournal.org).  The adjusted relative 
260 risks for systemic SAEs related to anti-VEGF treatment and those not related to anti-VEGF 
261 treatment were nearly identical (1.10 and 1.11, respectively) (Figures 4, 5 available at 
262 http://www.aaojournal.org).  There were too few gastrointestinal hemorrhages reported (1 for 
263 ranibizumab in GEFAL, 1 for ranibizumab in LUCAS) to add any meaningful information to the 
264 imbalance reported in CATT (7 for bevacizumab, 2 for ranibizumab).
265 The percentage of the variability in relative risks due to heterogeneity across studies, rather 
266 than to sampling error, is given by the I2 statistic in each of the Figures.  Heterogeneity was 
267 moderate for the proportion of patients with 1 or more systemic SAE (50%) and systemic SAEs 
12
268 not related to systemic anti-VEGF treatments (59%), substantially less (30%) for 
269 arteriothrombotic events, and 0% for death and events related to systemic anti-VEGF 
270 treatment. 
271 DISCUSSION 
272 The individual patient data meta-analyses yielded no significant differences in risk of 
273 systemic SAEs between bevacizumab and ranibizumab.  Thus, while the point estimate for 
274 relative risk indicated an approximate 10% increase with bevacizumab relative to ranibizumab 
275 for most categories of SAE, a similar 10% decrease for arteriothrombotic events was found.  
276 However, the confidence intervals for the relative risks spanned values, both for increased risk 
277 and decreased risk with bevacizumab, that would be clinically important for events such as 
278 death, cerebro- and cardio-vascular events, and cancer.  The adjusted analyses produced 
279 results indicating less risk with bevacizumab than in the unadjusted analyses; however, the 
280 reduction was minor.
281 Now that 10 years have passed since the introduction of bevacizumab and ranibizumab for 
282 treatment of neovascular age-related macular degeneration, new head-to-head trials are no 
283 longer likely to be performed.  Although the recent Cochrane meta-analyses of systemic SAEs 
284 and the unadjusted meta-analysis based on aggregated data reported here did not include the 
285 same set of trials, they yielded similar relative risks of approximately 1.1 for 1 or more SAEs 
286 through 1 or 2 years.  A trial in India of 120 patients with no adverse events reported,28 a trial in 
287 the United States of 28 patients with 2 deaths reported in 20 patients treated with bevacizumab 
288 (1 meckel cell carcinoma and 1 cause unknown),29 and a trial in Germany registered on 
289 ClinicalTrials.gov but without presentation at a national meeting or in a peer-reviewed journal 
290 were included in the meta-analysis by Moja but not the current one.30  Moja noted that, in a 
291 personal communication, the German researchers reported SAEs in 21% (22/107) of patients 
292 treated with bevacizumab and in 11% (6/54) of patients treated with ranibizumab.15  Because 
13
293 small imbalances on strong risk factors such as age, smoking history, hypertension, diabetes, 
294 and aspirin and anti-coagulant use can result in biased estimates of difference in risk, this 
295 review was initiated to find out whether such imbalances might have influenced the result of 
296 meta-analyses that used aggregate data from the clinical trials.  
297 There are some weaknesses in this meta-analysis.  First, all the trials were of modest size 
298 (<1200 patients each). Second, although there was a common definition of an SAE across 
299 trials, the methods of ascertaining the occurrence of an SAE may have varied among trials.  
300 Third, the dosing intervals varied across the trials.  Comparisons between the drugs were made 
301 within each dosing regimen, but the monthly, as needed, and treat and extend approaches were 
302 used among the trials.  Fourth, individual patient data could not be obtained for one of the 
303 clinical trials and only a secondary analysis using aggregate data from that trial could be 
304 performed.  Fifth, there was moderate heterogeneity across the 5 trials in the proportion of 
305 patients with 1 or more systemic SAE and systemic SAEs not related to systemic anti-VEGF 
306 treatments, due mainly to results from LUCAS.  We attribute this to random variation because 
307 eligibility, dose, and visual acuity results in LUCAS were similar to those in the other trials and 
308 the ascertainment of SAEs was made by staff masked to study drug.  In addition to the strength 
309 of the study of being able to account for possible imbalances in prognostic factors through use 
310 of patient-level data, the present study employed survival analysis methods that incorporate not 
311 only the occurrence of an SAE but also the time since initiation of treatment, thus providing a 
312 more precise assessment of differential risk than simply comparing the cumulative numbers at 
313 either 1 or 2 years of follow-up.
314 The meta-analyses on individual patient data in this review, as well as previous meta-
315 analyses on aggregate data, support the conclusion that large differences between 
316 bevacizumab and ranibizumab in risk of systemic serious adverse events; i.e., relative risks of 
317 ≥1.5, are unlikely.  Although the estimated relative risks indicate an approximate 10% increase 
14
318 for most types of SAEs and a 10% decrease in arteriothrombotic events for bevacizumab, these 
319 point estimates have confidence intervals that include up to a 50% increase or decrease in risk.  
320 In the absence of additional large-scale clinical trials, further investigation of the differential risk 
321 of these anti-VEGF agents can be carried out only though epidemiologic surveillance using 
322 administrative or healthcare databases.
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410 FIGURE LEGEND
411
412 Figure 1.  Forest Plot for the Adjusted Relative Risk for 1 or More Systemic Serious 
413 Adverse Events for Bevacizumab Compared to Ranibizumab.

Figure 2. (Supplementary) Forest Plot for the Adjusted Relative Risk for Death for Bevacizumab 
Compared to Ranibizumab 
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Figure 3. (Supplementary)  Forest Plot for the Adjusted Relative Risk for Antiplatelet Trialists’ Collaboration 
(APTC) Arteriothrombotic Event as for Bevacizumab Compared to Ranibizumab 
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Figure 4. (Supplementary)  Forest Plot for the Adjusted Relative Risk for Events Related to Anti-VEGF 
Treatment for Bevacizumab Compared to Ranibizumab 
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Figure 5. (Supplementary)  Forest Plot for the Adjusted Relative Risk for Events Not Related to Anti-VEGF 
Treatment for Bevacizumab Compared to Ranibizumab 
 
 
 
 Table 1.  Distribution of Baseline Characteristics Available from Each Clinical Trial by Drug 
 
  Clinical Trial 
 Characteristic  CATT IVAN GEFAL LUCAS BRAMD Overall 
Drug, N 
     
 
Bevacizumab 586 296 246 220 165 1513 
Ranibizumab 599 314 239 221 166 1539 
Age (yrs), mean 
     
 
Bevacizumab 79.7 77.7 79.5 78.6 77.1 78.8 
Ranibizumab 78.8 77.8 79.0 78.0 77.0 78.3 
Female (%) 
     
 
Bevacizumab 62.1 61.2 62.2 70.6 55.2 62.4 
Ranibizumab 61.4 58.9 70.3 64.2 55.4 62.0 
Current or past smoker (%) 
    
 
Bevacizumab 57.7 62.5 NA 55.5 54.6 58.0 
Ranibizumab 56.8 63.7 NA 52.0 51.8 57.0 
Diabetic (%) 
     
 
Bevacizumab 18.3 9.1 11.8 7.0 10.9 13.0 
Ranibizumab 16.7 11.8 10.9 6.4 12.7 12.9 
Hypertension (%) 
     
 
Bevacizumab 70.3 61.2 61.8 57.9 57.0 63.9 
Ranibizumab 68.6 59.9 53.1 53.2 66.9 62.0 
Aspirin (%) 
     
 
Bevacizumab 50.9 31.4 NA 29.0 NA 41.3 
Ranibizumab 45.9 27.1 NA 30.3 NA 37.7 
Anticoagulant (%) 
     
 
Bevacizumab 16.6 4.4 NA 7.7 NA 11.5 
Ranibizumab 17.7 6.1 NA 9.1 NA 12.8 
             
 
NA = Not available. 
 
 
 
 
 
Table 2.  Systemic Serious Event and its Type from Each Clinical Trial by Drug 
 
   
 Characteristic  CATT IVAN GEFAL LUCAS BRAMD  Total 
N  
     
 
 Bevacizumab 586 296 246 220 165  1513 
Ranibizumab 599 314 239 221 166  1539 
≥1 SAE: n (%)        
Bevacizumab 
234 
(39.9%) 
80 
(27.0%) 
30 
(12.2%) 
29 
(13.2%) 
30 
(18.2%) 
 403 
(26.6%) 
Ranibizumab 
190 
(31.7%) 
81 
(25.8%) 
24 
(10.0%) 
45 
(20.4%) 
26 
(15.7%) 
 366 
(23.8%) 
Death: n (%) 
     
 
 
Bevacizumab 
36 
(6.1%) 
15 
(5.1%) 
2 
(0.8%) 
4 
(1.8%) 
1  
(0.6%) 
 58  
(3.8%) 
Ranibizumab 
32 
(5.3%) 
15 
(4.8%) 
3 
(1.3%) 
7 
(3.2%) 
1  
(0.6%) 
 58  
(3.8%) 
APTC: n (%)       
 
Bevacizumab 
29 
(4.9%) 
20 
(6.8%) 
2 
(0.8%) 
3 
(1.4%) 
4  
(2.4%) 
 58 
 (3.8%) 
Ranibizumab 
28 
(4.7%) 
25 
(8.0%) 
1 
(0.4%) 
9 
(4.1%) 
2  
(0.9%) 
 65  
(4.2%) 
VEGF-related: n (%) 
    
 
 
Bevacizumab 
62 
(10.6%) 
14 
(4.7%) 
4 
(1.6%) 
6 
(2.7%) 
3  
(1.8%) 
 89  
(5.9%) 
Ranibizumab 
45 
(7.5%) 
19 
(6.1%) 
4 
(1.7%) 
8 
(3.6%) 
3  
(1.8%) 
 79  
(5.1%) 
Not VEGF-related: n (%)       
 
Bevacizumab 
202 
(34.4%) 
73 
(24.7%) 
27 
(11.0%) 
25 
(11.4%) 
29 
(17.6%) 
 356 
(23.5%) 
Ranibizumab 
170 
(28.4%) 
70 
(22.2%) 
20 
(8.4%) 
40 
(18.1%) 
23 
(13.9%) 
 323 
(21.0%) 
          
NA is not available.  
     
 
 APTC = Antiplatelet Trialists’ Collaboration arteriothrombotic events 
VEGF is vascular endothelial growth factor 
 
Table 3.  Summary of Estimated Relative Risks of Systemic Serious Adverse Events after 
Treatment with Bevacizumab Compared to Ranibizumab 
 
  Bevacizumab 
(N=1513) 
With Event 
Ranibizumab 
(N=1539) 
With Event 
      
Systemic 
Serious Relative Risk (95% CI) 
P-value 
Adjusted 
Model Event Type n (%)  n. (%)  Unadjusted  Adjusted 
   
1.08 1.06 
0.61 ≥1 event  403 (26.6%) 366 (23.8%)  (0.90,1.30)  (0.84,1.35) 
     
 
Death 58 (  3.8%) 58 ( 3.8%) 
1.03  
(0.72,1.48) 
0.99  
(0.69,1.43) 
 
0.97 
     
 
APTC 58 (  3.8%) 65 (  4.2%) 
0.93 
(0.66,1.32) 
0.89  
(0.62,1.28) 
 
0.53 
     
 
VEGF-related 89 (  5.9%) 79 (  5.1%) 
1.16 
(0.86,1.56) 
1.10  
(0.81,1.50) 
 
0.54 
     
 
Not 
  
1.14 1.11  
VEGF-related 356 (23.5%) 323 (21.0%)  (1.00,1.30)  (0.87,1.40) 0.40 
           
APTC is Antiplatelet Trialists’ Collaboration arteriothrombotic events 
VEGF is vascular endothelial growth factor 
 
Precis
A meta-analysis on individual patient data supports the conclusion that large differences 
between bevacizumab and ranibizumab in risk of systemic serious adverse events; i.e., relative 
risks of ≥1.5, are unlikely.
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Barkmeier, MD (O); Karin Berg, COA (VA/R); Jean Burrington, COA (VA/R); Albert Edwards, MD (O); 
Shannon Goddard, COA (OP/OCT); Shannon Howard (VA/R); Raymond Iezzi, MD (O); Denise 
Lewison, COA (OP/OCT); Thomas Link, CRA (OP/OCT); Colin A. McCannel, MD (O); Joan Overend 
(VA/R); John Pach, MD (O); Margaret Ruszczyk, CCRP (CC); Ryan Shultz, MD (O); Cindy Stephan, 
COT (VA/R); Diane Vogen (CC). 
 
Dean A. McGee Eye Institute (Oklahoma City, OK): Reagan H. Bradford Jr, MD (PI); Vanessa 
Bergman, COA, CCRC (CC); Russ Burris (OP/OCT); Amanda Butt, CRA (OP/OCT); Beth Daniels, 
COA (CC); Connie Dwiggins, CCRC (CC); Stephen Fransen, MD (O); Tiffany Guerrero (CC/DE); Darin 
Haivala, MD (O); Amy Harris (CC); Sonny Icks (CC/DE); Ronald Kingsley, MD (O); Lena Redden 
(VA/R); Rob Richmond (OP/OCT); Brittany Ross (VA/R); Kammerin White, CCRC (VA/R); Misty 
Youngberg, COA, CCRC (VA/R). 
 
Ophthalmic Consultants of Boston (Boston, MA): Trexler M. Topping, MD (PI); Steve Bennett 
(OCT); Sandy Chong (VA/R); Mary Ciotti, COA (CC); Tina Cleary, MD (O); Emily Corey (VA/R); 
Dennis Donovan (OP/OCT); Albert Frederick, MD (O); Lesley Freese (CC/VA/R); Margaret Graham 
(OP/OCT); Natalya Gud, COA (VA/R); Taneika Howard (VA/R); Mike Jones (OP/OCT); Michael 
Morley, MD (O); Katie Moses (VA/R); Jen Stone (VA/R); Robin Ty, COA (VA/R); Torsten Wiegand, 
PHD, MD (O); Lindsey Williams (CC); Beth Winder (CC). 
 
Tennessee Retina, P.C. (Nashville, TN): Carl C. Awh, MD (PI); Michelle Amonette (OCT); Everton 
Arrindell, MD (O); Dena Beck (OCT); Brandon Busbee, MD (O); Amy Dilback (OP/OCT); Sara Downs 
(VA/R); Allison Guidry, COA (VA/R); Gary Gutow, MD (O); Jackey Hardin (VA/R); Sarah Hines, COA 
(CC); Emily Hutchins (VA/R); Kim LaCivita, MA (OP/OCT); Ashley Lester (OP/OCT); Larry Malott 
(OP/OCT); MaryAnn McCain, RN, CNOR (CC); Jayme Miracle (VA/R); Kenneth Moffat, MD (O); Lacy 
Palazzotta (VA/R); Kelly Robinson, COA (VA/R); Peter Sonkin, MD (O); Alecia Travis (OP/OCT); Roy 
Trent Wallace, MD (O); Kelly J. Winters, COA (CC); Julia Wray (OP/OCT). 
 
Retina Associates Southwest, P.C. (Tucson, AZ): April E. Harris, MD (PI); Mari Bunnell (OCT); 
Katrina Crooks (VA/R); Rebecca Fitzgerald, CCRC (CC/OCT); Cameron Javid, MD (O); Corin Kew 
(VA/R); Erica Kill, VAE (VA/R); Patricia Kline (VA/R); Janet Kreienkamp (VA/R); Maricruz Martinez 
(CC/OCT); Roy Ann Moore, OMA (CC/OCT); Egbert Saavedra, MD (O); LuAnne Taylor, CSC 
(CC/OCT); Mark Walsh, MD (O); Larry Wilson (OP). 
 
Midwest Eye Institute (Indianapolis, IN): Thomas A. Ciulla, MD (PI); Ellen Coyle, COMT (VA/R); 
Tonya Harrington, COA (VA/R); Charlotte Harris, COA (VA/OCT); Cindi Hood (OCT); Ingrid Kerr, COA 
(VA/R); Raj Maturi, MD (O); Dawn Moore (OCT); Stephanie Morrow, COA (OP); Jennifer Savage, 
COA (VA); Bethany Sink, COA (CC/VA/R); Tom Steele, CRA (OP); Neelam Thukral, CCRC 
(CC/OCT); Janet Wilburn, COA (CC). 
 
National Ophthalmic Research Institute (Fort Myers, FL): Joseph P. Walker, MD (PI); Jennifer 
Banks (VA/R); Debbie Ciampaglia (OP/OCT); Danielle Dyshanowitz (VA/R); Jennifer Frederick, CRC 
(CC); A. Tom Ghuman, MD (O); Richard Grodin, MD (O); Cheryl Kiesel, CCRC (CC); Eileen Knips, 
RN, CCRC, CRA (OP/OCT); Jonathan McCue (VA/R); Maria Ortiz (VA/R); Crystal Peters, CCRC (CC); 
Paul Raskauskas, MD (O); Etienne Schoeman (OP/OCT); Ashish Sharma, MD (O); Glenn Wing, MD 
(O), Rebecca Youngblood (CC). 
 
University of Wisconsin Madison (Madison, WI): Suresh R. Chandra, MD (PI); Michael Altaweel, 
MD (O); Barbara Blodi, MD (O); Kathryn Burke, BA (VA/R); Kristine A. Dietzman, (CC); Justin Gottlieb, 
MD (O); Gene Knutson (OP/OCT); Denise Krolnik (OP/OCT); T. Michael Nork, MD (O); Shelly Olson 
(VA/R); John Peterson, CRA (OP/OCT); Sandra Reed (OP/OCT); Barbara Soderling (VA/R); Guy 
Somers (VA/R); Thomas Stevens, MD (O); Angela Wealti, (CC). 
 
Duke University Eye Center (Durham, NC): Srilaxmi Bearelly, MD (PI); Brenda Branchaud (VA/R); 
Joyce W. Bryant, COT, CPT (CC/VA/R); Sara Crowell (CC/VA); Sharon Fekrat, MD (O); Merritt 
Gammage (OP/OCT); Cheala Harrison, COA (VA/R); Sarah Jones (VA); Noreen McClain, COT, CPT, 
CCRC (VA/R); Brooks McCuen, MD (O); Prithvi Mruthyunjaya, MD (O); Jeanne Queen, CPT 
(OP/OCT); Neeru Sarin, MBBS (VA/R); Cindy Skalak, RN, COT (VA/R); Marriner Skelly, CRA 
(OP/OCT); Ivan Suner, MD (O); Ronnie Tomany (OP/OCT); Lauren Welch (OP/OCT). 
 
University of California-Davis Medical Center (Sacramento, CA): Susanna S. Park, MD, PHD (PI); 
Allison Cassidy (VA/R); Karishma Chandra (OP/OCT); Idalew Good (VA/R); Katrina Imson (CC); Sashi 
Kaur (OP/OCT); Helen Metzler, COA, CCRP (CC/VA/R); Lawrence Morse, MD, PHD (O); Ellen 
Redenbo, ROUB (OP/OCT); Marisa Salvador (VA/R); David Telander, MD (O); Mark Thomas, CRA 
(OCT); Cindy Wallace, COA (CC). 
 
University of Louisville School of Medicine, KY (Louisville, KY): Charles C. Barr, MD (PI); 
Amanda Battcher (VA/R); Michelle Bottorff, COA (CC/OCT); Mary Chasteen (VA/R); Kelly Clark 
(VA/R); Diane Denning, COT (OCT); Debra Schoen (OP); Amy Schultz (OP); Evie Tempel, CRA, COA 
(OP); Lisa Wheeler, COT (VA/R); Greg K. Whittington, MPS, PSY (CC). 
 
Retina Associates of Kentucky (Lexington, KY): Thomas W. Stone, MD (PI); Todd Blevins 
(OP/OCT); Michelle Buck, COT, (VA/R/OCT); Lynn Cruz, COT (CC); Wanda Heath (VA/R); Diana 
Holcomb (VA/R); Rick Isernhagen, MD (O); Terri Kidd, COA (OCT); John Kitchens, MD (O); Cathy 
Sears, CST, COA (VA/R); Ed Slade, CRA, COA (OP/OCT); Jeanne Van Arsdall, COA (VA/R); Brenda 
VanHoose, COA (VA/R); Jenny Wolfe, RN (CC); William Wood, MD (O). 
 
Colorado Retina Associates (Denver, CO): John Zilis, MD (PI); Carol Crooks, COA (VA/R); Larry 
Disney (VA/R); Mimi Liu, MD (O); Stephen Petty, MD (O); Sandra Sall, ROUB, COA 
(CC/VA/R/OP/OCT). 
 
University of Iowa Hospitals & Clinics (Iowa City, IA): James C. Folk, MD (PI); Tracy Aly, CRA 
(OP/OCT); Abby Brotherton (VA); Douglas Critser, CRA (OP/OCT); Connie J. Hinz, COT, CCRC 
(CC/VA/R); Stefani Karakas, CRA (OP/OCT); Valerie Kirschner (VA); Cheyanne Lester (VA/R); Cindy 
Montague, CRA (OP/OCT); Stephen Russell, MD (O); Heather Stockman (VA/R); Barbara Taylor, 
CCRC (VA/R); Randy Verdick, FOPS (OP/OCT), Jean Walshire (CC). 
 
Retina Specialists (Towson, MD): John T. Thompson, MD (PI) ; Barbara Connell (VA/R); Maryanth 
Constantine (CC); John L. Davis Jr (VA/R); Gwen Holsapple (VA/R); Lisa Hunter (OP/OCT); C. Nicki 
Lenane (CC/VA/R/OP/OCT); Robin Mitchell (CC); Leslie Russel, CRA (OP/OCT); Raymond Sjaarda, 
MD (O). 
 
Retina Consultants of Houston (Houston, TX): David M. Brown, MD (PI); Matthew Benz, MD (O); 
Llewellyn Burns (OCT); JoLene G. Carranza, COA, CCRC (CC); Richard Fish, MD (O); Debra Goates 
(VA/R); Shayla Hay (VA/R); Theresa Jeffers, COT (VA/R); Eric Kegley, CRA, COA (OP/OCT); Dallas 
Kubecka (VA/R); Stacy McGilvra (VA/R); Beau Richter (OCT); Veronica Sneed, COA (VA/R); Cary 
Stoever (OCT); Isabell Tellez (VA/R); Tien Wong, MD (O). 
 
Massachusetts Eye and Ear Infirmary/Harvard Vanguard Medical Associates (Boston, MA): 
Ivana Kim, MD (PI); Christopher Andreoli, MD (O); Leslie Barresi, CRA, COA, OCT-C (VA/OP/OCT); 
Sarah Brett (OP); Charlene Callahan (OP); Karen Capaccioli (OCT); William Carli, COA (VA/R/OCT); 
Matthew Coppola, COA (VA); Nicholas Emmanuel (CC); Claudia Evans, OD (VA/R); Anna Fagan, 
COA (VA/R); Marcia Grillo (OCT); John Head, CRA, OCT-C (OP/OCT); Troy Kieser, COA, OCT-C 
(CC/VA/R); Elaine Lee, COA (VA); Ursula Lord, OD (VA/R); Edward Miretsky (CC); Kate Palitsch 
(OP/OCT); Todd Petrin, RN (OCT); Liz Reader (CC); Svetlana Reznichenko, COA (VA); Mary 
Robertson, COA (VA); Justin Smith, OD (VA/R); Demetrios Vavvas, MD, PHD (O). 
 
Palmetto Retina Center (West Columbia, SC): John Wells, MD (PI); Cassie Cahill (VA/R); W. Lloyd 
Clark, MD (O); Kayla Henry (VA/R); David Johnson, MD (O); Peggy Miller (CC/VA/R); LaDetrick 
Oliver, COT (OP/OCT); Robbin Spivey (OP/OCT); Tiffany Swinford (VA/R); Mallie Taylor (CC). 
 
Retina and Vitreous of Texas (Houston, TX): Michael Lambert, MD (PI); Kris Chase (OP/OCT); 
Debbie Fredrickson, COA (VA/R); Joseph Khawly, MD, FACS (O); Valerie Lazarte (VA/R); Donald 
Lowd (OP/OCT); Pam Miller (CC); Arthur Willis, MD (O). 
 
Long Island Vitreoretinal Consultants (Great Neck, NY): Philip J. Ferrone, MD (PI); Miguel Almonte 
(OCT); Rachel Arnott, (CC); Ingrid Aviles (VA/R/OCT); Sheri Carbon (VA/R); Michael Chitjian 
(OP/OCT); Kristen DAmore (CC); Christin Elliott (VA/R); David Fastenberg, MD (O); Barry Golub, MD 
(O); Kenneth Graham, MD (O); AnnMarie Lavorna (CC); Laura Murphy (VA/R); Amanda Palomo 
(VA/R); Christina Puglisi (VA/R); David Rhee, MD (O); Juan Romero, MD (O); Brett Rosenblatt, MD 
(O); Glenda Salcedo (OP/OCT); Marianne Schlameuss, RN (CC); Eric Shakin, MD (O); Vasanti 
Sookhai (VA/R). 
 
Wills Eye Institute/ Mid Atlantic Retina (Philadelphia, PA): Richard Kaiser, MD (PI); Elizabeth Affel, 
MS, OCT-C (OCT); Gary Brown, MD (O); Christina Centinaro (CC); Deborah Fine, COA (OCT); 
Mitchell Fineman, MD (O); Michele Formoso (CC); Sunir Garg, MD (O); Lisa Grande (VA/R); Carolyn 
Herbert (VA/R); Allen Ho, MD (O); Jason Hsu, MD (O); Maryann Jay (OCT); Lisa Lavetsky (OCT); 
Elaine Liebenbaum (OP); Joseph Maguire, MD (O); Julia Monsonego (OP/OCT); Lucia O’Connor 
(OCT); Lisa Pierce (CC); Carl Regillo, MD (O); Maria Rosario (DE); Marc Spirn, MD (O); James 
Vander, MD (O); Jennifer Walsh (VA/R). 
 
Ohio State University Eye Physicians & Surgeons-Retina Division (Dublin, OH): Frederick H. 
Davidorf, MD (PI); Amanda Barnett (OP/OCT); Susie Chang, MD (O); John Christoforidis, MD (O); Joy 
Elliott (CC); Heather Justice (VA/R); Alan Letson, MD (O); Kathryne McKinney, COMT (CC); Jeri 
Perry, COT (VA/R); Jill A. Salerno, COA (CC); Scott Savage (OP); Stephen Shelley (OCT). 
 
Retina Associates of Cleveland (Beachwood, OH): Lawrence J. Singerman, MD (PI);Joseph 
Coney, MD (O); John DuBois (OP/OCT); Kimberly DuBois, LPN, CCRP, COA (VA/R); Gregg Greanoff, 
CRA (OP/OCT); Dianne Himmelman, RN, CCRC (CC); Mary Ilc, COT (VA/R); Elizabeth Mcnamara 
(VA/R/OP); Michael Novak, MD (O); Scott Pendergast, MD (O); Susan Rath, PA-C (CC); Sheila Smith-
Brewer, CRA (OP/OCT); Vivian Tanner, COT, CCRP (VA/R); Diane E. Weiss, RN, (CC); Hernando 
Zegarra, MD (O). 
 
Retina Group of Florida (Fort Lauderdale, FL): Lawrence Halperin, MD (PI); Patricia Aramayo 
(OCT); Mandeep Dhalla, MD (O); Brian Fernandez, MD (OP/OCT); Cindy Fernandez, MD (CC); Jaclyn 
Lopez (CC); Monica Lopez (OCT); Jamie Mariano, COA (VA/R); Kellie Murphy, COA (OCT); Clifford 
Sherley, COA (VA/R); Rita Veksler, COA (OP/OCT). 
 
Retina-Vitreous Associates Medical Group (Beverly Hills, CA): Firas Rahhal, MD (PI); Razmig 
Babikian (DE); David Boyer, MD (O); Sepideh Hami (DE); Jeff Kessinger (OP/OCT); Janet Kurokouchi 
(CC); Saba Mukarram (VA/R); Sarah Pachman (VA/R); Eric Protacio (OCT); Julio Sierra (VA/R); 
Homayoun Tabandeh, MD, MS, FRCP (O); Adam Zamboni (VA/R). 
 
Elman Retina Group, P.A. (Baltimore, MD): Michael Elman, MD (PI); Jennifer Belz (CC); Tammy 
Butcher (CC); Theresa Cain (OP/OCT); Teresa Coffey, COA (VA/R); Dena Firestone (VA/R); Nancy 
Gore (VA/R); Pamela Singletary (VA/R); Peter Sotirakos (OP/OCT); JoAnn Starr (CC). 
 
University of North Carolina at Chapel Hill (Chapel Hill, NC): Travis A. Meredith, MD (PI); 
Cassandra J. Barnhart, MPH (CC/VA/R); Debra Cantrell, COA (VA/R/OP/OCT); RonaLyn Esquejo-
Leon (OP/OCT); Odette Houghton, MD (O); Harpreet Kaur (VA/R); Fatoumatta NDure, COA (CC). 
 
Ophthalmologists Enrolling Patients but No Longer Affiliated with a CATT Center: Ronald 
Glatzer, MD (O); Leonard Joffe, MD (O); Reid Schindler, MD (O). 
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Chairman’s Office (Cleveland Clinic, Cleveland, OH):  Daniel F. Martin, MD (Chair); Stuart L. Fine, 
MD (Vice-Chair; University of Colorado, Denver, CO); Marilyn Katz (Executive Assistant).  
 
Coordinating Center (University of Pennsylvania, Philadelphia, PA): Maureen G. Maguire, PhD 
(PI); Mary Brightwell-Arnold, SCP (Systems Analyst); Ruchira Glaser, MD (Medical Monitor); 
Judith Hall (Protocol Monitor); Sandra Harkins (Staff Assistant); Jiayan Huang, MS (Biostatistician); 
Alexander Khvatov, MS (Systems Analyst); Kathy McWilliams, CCRP (Protocol Monitor); Susan K. 
Nolte (Protocol Monitor); Ellen Peskin, MA, CCRP (Project Director); Maxwell Pistilli, MS, MEd 
(Biostatistician); Susan Ryan (Financial Administrator); Allison Schnader (Administrative Coordinator); 
Gui-Shuang Ying, PhD (Senior Biostatistician). 
 
OCT Reading Center (Duke University, Durham, NC):  Glenn Jaffe, MD (PI); Jennifer Afrani-Sakyi 
(CATT PowerPoint Presentations); Brannon Balsley (OCT Technician Certifications); Linda S. Bennett 
(Project Manager); Adam Brooks (Reader/SD-Reader); Adrienne Brower-Lingsch (Reader); Lori Bruce 
(Data Verification); Russell Burns (Senior Technical Analyst/Senior Reader/SD Reader/OCT Technician 
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DuBois (Data Entry); Mays El-Dairi (Reader/SD-Reader); Sarah Gach (Reader); Katelyn Hall (Project 
Manager/Reader Reliability Studies/ Data Verification/Document Creation); Terry Hawks (Reader); 
ChengChenh Huang (Reader); Cindy Heydary (Senior Reader/Quality Assurance Coordinator/SD 
Reader/Data Verification); Alexander Ho (Reader, Transcription); Shashi Kini (Data 
Entry/Transcription); Michelle McCall (Data Verification); Daaimah Muhammad (Reader Feedback); 
Jayne Nicholson (Data Verification); Jeanne Queen (Reader/SD-Reader); Pamela Rieves 
(Transcription); Kelly Shields (Senior Reader); Cindy Skalak (Reader); Adam Specker (Reader); 
Sandra Stinnett (Biostatistician); Sujatha Subramaniam (Reader); Patrick Tenbrink (Reader); Cynthia 
Toth, MD (Director of Grading); Aaron Towe (Reader); Kimberly Welch (Data Verification); Natasha 
Williams (Data Verification); Katrina Winter (Senior Reader); Ellen Young (Senior Project Manager). 
 
Fundus Photograph Reading Center (University of Pennsylvania, Philadelphia, PA):  Juan E. 
Grunwald, MD (PI); Judith Alexander (Director); Ebenezer Daniel, MBBS, MS, MPH, PhD (Director); 
Elisabeth Flannagan (Administrative Coordinator); E. Revell Martin (Reader); Candace Parker 
(Reader); Krista Sepielli (Reader); Tom Shannon (Systems Analyst); Claressa Whearry (Data 
Coordinator). 
 
National Eye Institute, National Institutes of Health:  Maryann Redford, DDS, MPH (Program 
Officer). 
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